TY - JOUR
T1 - Dendritic cell derived-exosomes
T2 - Biology and clinical implementations
AU - Chaput, Nathalie
AU - Flament, Caroline
AU - Viaud, Sophie
AU - Taieb, Julien
AU - Roux, Stephan
AU - Spatz, Alain
AU - André, Fabrice
AU - LePecq, Jean Bernard
AU - Boussac, Muriel
AU - Garin, Jérôme
AU - Amigorena, Sebastian
AU - Théry, Clotilde
AU - Zitvogel, Laurence
PY - 2006/9/1
Y1 - 2006/9/1
N2 - Exosomes are nanometer-sized membrane vesicles invaginating from multivesicular bodies and secreted from different cell types. They represent an "in vitro" discovery, but vesicles with the hallmarks of exosomes are present in vivo in germinal centers and biological fluids. Their protein and lipid composition is unique and could account for their expanding functions such as eradication of obsolete proteins, antigen presentation, or "Trojan horses" for viruses or prions. The potential of dendritic cell-derived exosomes (Dex) as cell-free cancer vaccines is addressed in this review. Lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities of Dex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients.
AB - Exosomes are nanometer-sized membrane vesicles invaginating from multivesicular bodies and secreted from different cell types. They represent an "in vitro" discovery, but vesicles with the hallmarks of exosomes are present in vivo in germinal centers and biological fluids. Their protein and lipid composition is unique and could account for their expanding functions such as eradication of obsolete proteins, antigen presentation, or "Trojan horses" for viruses or prions. The potential of dendritic cell-derived exosomes (Dex) as cell-free cancer vaccines is addressed in this review. Lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities of Dex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients.
KW - Clinical trial
KW - Cytotoxic T lymphocytes
KW - Nk cells
KW - Tumor immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=33751504617&partnerID=8YFLogxK
U2 - 10.1189/jlb.0206094
DO - 10.1189/jlb.0206094
M3 - Review article
C2 - 16809645
AN - SCOPUS:33751504617
SN - 0741-5400
VL - 80
SP - 471
EP - 478
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
IS - 3
ER -